KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Change in Receivables (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed Change in Receivables for 13 consecutive years, with $765000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 27.07% to $765000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $268000.0 through Dec 2025, down 77.78% year-over-year, with the annual reading at $268000.0 for FY2025, 77.78% down from the prior year.
  • Change in Receivables hit $765000.0 in Q4 2025 for ClearPoint Neuro, up from -$260000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.2 million in Q2 2022 to a low of -$846000.0 in Q1 2024.
  • Historically, Change in Receivables has averaged $207350.0 across 5 years, with a median of $207500.0 in 2021.
  • Biggest five-year swings in Change in Receivables: surged 489.47% in 2023 and later tumbled 559.78% in 2024.
  • Year by year, Change in Receivables stood at -$190000.0 in 2021, then plummeted by 305.79% to -$771000.0 in 2022, then surged by 248.12% to $1.1 million in 2023, then dropped by 8.14% to $1.0 million in 2024, then dropped by 27.07% to $765000.0 in 2025.
  • Business Quant data shows Change in Receivables for CLPT at $765000.0 in Q4 2025, -$260000.0 in Q3 2025, and $609000.0 in Q2 2025.